GlassScriptPhysician profile
Krista Michellle Molina
NPI 1861697781
$2,284.34
in general payments reported to CMS, 2019-2025
31 companies · $14.57 in 2025
The $14.57 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,142 · 2020: $336 · 2022: $11.71 · 2023: $357 · 2024: $423 · 2025: $14.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $225.90 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $206.56 | 2019-2024 | Flumist Quadrivalent |
| Novo Nordisk INC | $192.53 | 2019-2024 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.13 | 2019-2023 | Jardiance, Synjardy |
| Allergan, INC. | $173.43 | 2019-2020 | |
| Abbvie INC. | $148.02 | 2019-2024 | |
| Astellas Pharma US INC | $111.14 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $109.71 | 2019 | |
| Janssen Pharmaceuticals, INC | $109.04 | 2019 | |
| Corcept Therapeutics | $100.52 | 2023-2024 | Korlym |
| Pfizer INC. | $67.50 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.07 | 2019 | |
| Amarin Pharma, INC. | $57.62 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $54.57 | 2019-2020 | |
| Glaxosmithkline, LLC. | $54.04 | 2019-2025 | Shingrix, Arexvy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $47.57 | 2024 | |
| Bausch Health US, LLC | $43.79 | 2019-2020 | |
| Abbott Laboratories | $43.46 | 2023-2024 | Freestyle Libre 3 |
| Almatica Pharma LLC | $42.49 | 2023-2024 | Loreev Xr, Gralise |
| Exact Sciences Corporation | $35.99 | 2023-2024 | Cologuard Collection Kit |
| Jazz Pharmaceuticals INC. | $32.19 | 2019 | |
| Upsher-Smith Laboratories LLC | $32.10 | 2019-2020 | |
| Adlon Therapeutics L.P. | $26.63 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $23.62 | 2024 | Rexulti |
| Shire North American Group INC | $17.79 | 2019 | |
| Amgen INC. | $16.77 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.26 | 2023 | |
| Dexcom, INC. | $14.07 | 2023 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $13.91 | 2019 | |
| Bio Products Laboratory USA, INC. | $11.49 | 2023 | Gammaplex, Coagadex |
| Sunovion Pharmaceuticals INC. | $10.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krista Molina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.